Replek AD (XMAE:REPL) Debt-to-Equity : 0.18 (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Replek AD Debt-to-Equity?

Replek AD's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was MKD238 Mil. Replek AD's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was MKD184 Mil. Replek AD's Total Stockholders Equity for the quarter that ended in Dec. 2024 was MKD2,368 Mil. Replek AD's debt to equity for the quarter that ended in Dec. 2024 was 0.18.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Replek AD's Debt-to-Equity or its related term are showing as below:

XMAE:REPL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.12 Max: 0.19
Current: 0.18

During the past 13 years, the highest Debt-to-Equity Ratio of Replek AD was 0.19. The lowest was 0.04. And the median was 0.12.

XMAE:REPL's Debt-to-Equity is ranked better than
61.12% of 818 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs XMAE:REPL: 0.18

Replek AD Debt-to-Equity Historical Data

The historical data trend for Replek AD's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replek AD Debt-to-Equity Chart

Replek AD Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.13

0.12

0.19

0.12

0.18

Replek AD Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.12	0.17	N/A	0.18

Competitive Comparison of Replek AD's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Replek AD's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Replek AD's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Replek AD's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Replek AD's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Replek AD Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Replek AD's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(237.696	+	183.669)	/	2367.888
	=	0.18

Replek AD's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(237.696	+	183.669)	/	2367.888
	=	0.18

Replek AD (XMAE:REPL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Replek AD Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Replek AD's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Replek AD Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Replek AD (XMAE:REPL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kozle 188, Skopje, MKD

Website

https://www.replek.mk

Replek AD is engaged in the development, design and production of generic medicines. The company develops drugs in different pharmaceutical therapeutic categories including anti-platelet, lipid-lowering, atypical antipsychotic, anti-infective, among others. It manufactures drugs in different forms including tablets, capsules, oral solutions, creams and ointments. Its product portfolio consists of Clopidogrel, Atorvastatin, Simvastatin, risperidone, Clarythromycin, Ciprofloxacin, Meloksikam, Risperidon, terazosin, among others. Replek also offers cannabis oil products, food supplements and cosmetics.